ArticleThe Analyst2012
Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling.
Article in The Analyst, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Label-free interferometry platform for drug response profiling of bioprinted tumor organoids at single-organoid resolution.Nature protocols · 2026Review
- Tracking of lineage massLab on a chip · 2024Article
- LVING reveals the intracellular structure of cell growth.Scientific reports · 2024Article
- Drug screening at single-organoid resolution via bioprinting and interferometry.Nature communications · 2023Article
- Review
- Microfluidic Single-Cell Analytics.Advances in biochemical engineering/biotechnology · 2022Article
- Identifying fates of cancer cells exposed to mitotic inhibitors by quantitative phase imaging.The Analyst · 2019Article
- Article
- Fabrication of Refractive-index-matched Devices for Biomedical Microfluidics.Journal of visualized experiments : JoVE · 2018Article
- Soft lithography fabrication of index-matched microfluidic devices for reducing artifacts in fluorescence and quantitative phase imaging.Microfluidics and nanofluidics · 2018Article
- Hybrid random walk-linear discriminant analysis method for unwrapping quantitative phase microscopy images of biological samples.Journal of biomedical optics · 2015Article
- Live-cell mass profiling: an emerging approach in quantitative biophysics.Nature methods · 2014Article
- Label-free high-throughput cell screening in flow.Biomedical optics express · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Live cell mass profiling is a promising new approach for rapidly quantifying responses to therapeutic agents through picogram-scale changes in cell mass over time. A significant barrier in mass profiling is the inability of existing methods to handle pleomorphic cellular clusters and clumps, which are more commonly present in patient-derived samples or tissue cultures than are isolated single cells. Here we demonstrate automated Live Cell Interferometry (LCI) as a rapid and accurate quantifier of the sensitivity of single cell and colony-forming human breast cancer cell lines to the HER2-directed monoclonal antibody, trastuzumab (Herceptin). The relative sensitivities of small samples (<500 cells) of four breast cancer cell lines were determined tens-to-hundreds of times faster than is possible with traditional proliferation assays. These LCI advances in clustered sample assessment and speed open up the possibility for therapeutic response testing of patient-derived solid tumor samples, which are viable only for short periods ex vivo and likely to be in the form of cell aggregates and clusters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.